HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$0.85 USD
+0.09 (11.11%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.84 -0.01 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for HOOKIPA Pharma Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 117 | 113 | 66 | 143 | 113 |
Receivables | 19 | 22 | 21 | 21 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 12 | 14 | 8 | 5 |
Total Current Assets | 147 | 147 | 102 | 172 | 128 |
Net Property & Equipment | 8 | 18 | 16 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 2 | 1 |
Total Assets | 161 | 170 | 126 | 188 | 144 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 5 | 9 | 8 | 1 |
Current Portion Long-Term Debt | 1 | 2 | 3 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 11 | 9 | 7 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 16 | 6 | 4 | 4 |
Total Current Liabilities | 42 | 36 | 28 | 21 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 20 | 26 | 0 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 2 | 5 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 3 | 3 | 1 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 71 | 68 | 36 | 32 | 26 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 467 | 397 | 317 | 309 | 226 |
Retained Earnings | -369 | -288 | -223 | -147 | -103 |
Other Equity | -8 | -7 | -5 | -6 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 90 | 103 | 90 | 156 | 118 |
Total Liabilities & Shareholder's Equity | 161 | 170 | 126 | 188 | 144 |
Total Common Equity | 90 | 103 | 90 | 156 | 118 |
Shares Outstanding | 98.90 | 54.70 | 31.20 | 21.80 | 21.50 |
Book Value Per Share | 0.91 | 1.87 | 2.87 | 7.16 | 5.48 |
Fiscal Year End for HOOKIPA Pharma Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 117 | 108 | 136 | 110 |
Receivables | NA | 19 | 23 | 20 | 18 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 11 | 9 | 12 | 12 |
Total Current Assets | NA | 147 | 139 | 168 | 140 |
Net Property & Equipment | NA | 8 | 20 | 18 | 18 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 2 | 1 | 2 |
Total Assets | NA | 161 | 164 | 191 | 163 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 13 | 9 | 12 | 7 |
Current Portion Long-Term Debt | NA | 1 | 1 | 1 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 13 | 12 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 15 | 16 | 20 | 19 |
Total Current Liabilities | NA | 42 | 41 | 46 | 44 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 20 | 24 | 27 | 30 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 3 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 71 | 69 | 79 | 80 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 467 | 446 | 445 | 398 |
Retained Earnings | NA | -369 | -344 | -325 | -307 |
Other Equity | NA | -8 | -6 | -7 | -7 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 90 | 95 | 112 | 83 |
Total Liabilities & Shareholder's Equity | NA | 161 | 164 | 191 | 163 |
Total Common Equity | 0 | 90 | 95 | 112 | 83 |
Shares Outstanding | 98.90 | 98.90 | 83.90 | 83.90 | 54.70 |
Book Value Per Share | 0.00 | 0.91 | 1.13 | 1.34 | 1.53 |